

10/523,753RCE

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/CAPplus Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/CAPplus updated with revised CAS roles
NEWS	7	JAN 22	CA/CAPplus enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	33	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	34	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability

10/523,753RCE

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:24:58 ON 22 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:25:12 ON 22 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAY 2007 HIGHEST RN 935505-97-8

DICTIONARY FILE UPDATES: 21 MAY 2007 HIGHEST RN 935505-97-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10523753RCE1.str



chain nodes :

7 14 21 22 23 25 26 29 30

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13 15 16 17 18 19 20

chain bonds :

5-7 7-8 10-14 14-15 21-22 22-23 25-26

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20
16-17 17-18 18-19 19-20

exact/norm bonds :

5-7 7-8 10-14 14-15 25-26

exact bonds :

21-22 22-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20
16-17 17-18 18-19 19-20

isolated ring systems :

containing 8 :

G1:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 29:CLASS 30:CLASS
32:Atom 33:Atom

10/523,753RCE

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:25:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

 BATCH **COMPLETE**

PROJECTED ITERATIONS: 704 TO 1616


PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> d scan

10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Thiopheneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl)methylene]- (9CI)
MF C26 H20 N6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):7

10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1H-Pyrrole-2-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-1-methyl- (9CI)

MF C27 H23 N7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzonitrile, 4-[[5-(2-amino-5-thiazolyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-

MF C25 H20 N8 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-
[(3-furanylmethyl)amino]-2-pyrimidinyl]amino]- (9CI)

MF C27 H23 N7 O

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-
[[4-pyridinylmethoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI)

MF C29 H24 N8 O

Double bond geometry as described by E or Z.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[methyl(1,2,3-thiadiazol-4-ylmethyl)amino]-2-pyrimidinyl]amino]- (9CI)

MF C26 H23 N9 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Formamide, N-[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-
[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI)

MF C21 H13 Cl F N7 O

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/523,753RCE

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-methylethenyl]-2,6-
dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI)
MF C23 H20 N6

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/523,753RCE

=> s l1 sss ful

FULL SEARCH INITIATED 16:26:14 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1337 TO ITERATE

100.0% PROCESSED 1337 ITERATIONS

222 ANSWERS

SEARCH TIME: 00.00.01

L3 222 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 16:26:21 ON 22 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 May 2007 VOL 146 ISS 22

FILE LAST UPDATED: 21 May 2007 (20070521/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3


L4 42 L3

=> d l4 1-42 bib hitstr

10/523,753RCE

L4 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:407469 CAPLUS
DN 146:414238
TI The prediction of drug metabolism, tissue distribution, and
bioavailability of 50 structurally diverse compounds in rat using
mechanism-based absorption, distribution, and metabolism prediction tools
AU De Buck, Stefan S.; Sinha, Vikash K.; Fenu, Luca A.; Gilissen, Ron A.;
Mackie, Claire E.; Nijssen, Marjoleen J.
CS Discovery ADME-Tox Department, Johnson and Johnson Pharmaceutical Research
and Development, Beerse, Belg.
SO Drug Metabolism and Disposition (2007), 35(4), 649-659
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 500287-72-9, Rilpivirine
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)
(prediction model of drug metabolism, distribution, and bioavailability of
50 structurally diverse compds.)
RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/523,753RCE

L4 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:343359 CAPLUS
DN 146:434267
TI A dual chamber model of female cervical mucosa for the study of HIV
transmission and for the evaluation of candidate HIV microbicides
AU Van Herrewege, Yven; Michiels, Jo; Waeytens, Anouk; De Boeck, Gitte;
Salden, Evelyne; Heyndrickx, Leo; Van den Mooter, Guy; De Bethune,
Marie-Pierre; Andriès, Koen; Lewi, Paul; Praet, Marleen; Vanham, Guido
CS Virology Unit, Department of Microbiology, Institute of Tropical Medicine,
Antwerpen, B-2000, Belg.
SO Antiviral Research (2007), 74(2), 111-124
CODEN: ARSRDR; ISSN: 0166-3542
PB Elsevier B.V.
DT Journal
LA English
IT 244767-86-0, R152929 500287-72-9, R278474
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(dual chamber model of female cervical mucosa for study of HIV
transmission and for evaluation of candidate HIV microbicides)
RN 244767-86-0 CAPLUS
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-
dimethyl- (CA INDEX NAME)



RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



10/523,753RCE

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:175576 CAPLUS

DN 146:258964

TI Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome p450 enzymes and membrane efflux systems following vaginal and oral cavity administration

IN Pauletti, Giovanni M.; Harrison, Donald C.; Desai, Kishorkumar J.

PA USA

SO U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 208,209.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007036834	A1	20070215	US 2006-522126	20060915
	AU 765269	B2	20030911	AU 2001-54192	20010703
	US 2003049302	A1	20030313	US 2002-226667	20020821
	US 6982091	B2	20060103		
	US 2006002966	A1	20060105	US 2005-208209	20050818
	WO 2007035515	A2	20070329	WO 2006-US36087	20060915

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI	US 2001-315877P	P	20010829
	US 2002-226667	A1	20020821
	US 2005-208209	A2	20050818
	US 2005-717680P	P	20050915
	AU 1998-76976	A3	19980610

IT 500287-72-9, TMC278

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P 450 enzymes and membrane efflux systems following vaginal and oral cavity administration)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.

10/523,753RCE




10/523,753RCE

L4 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1285816 CAPLUS
DN 146:45547
TI Preparation of aryl bicyclo and spiro compounds as therapeutic modulators
of CCR-5 activity
IN Boman, Erik; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Lum,
Christopher; Sebo, Lubomir; Urban, Jan
PA Kemia, Inc., USA
SO PCT Int. Appl., 235pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006130426	A2	20061207	WO 2006-US20255	20060525
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-685147P	P	20050527		
	US 2006-785090P	P	20060322		
OS	MARPAT 146:45547				
IT	500287-72-9, Rilpivirine				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(addnl. therapeutic agent; preparation of aryl bicyclo and spiro compds. as therapeutic modulators of CCR-5 activity)				
RN	500287-72-9 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)				

Double bond geometry as shown.



10/523,753RCE

L4 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1283330 CAPLUS
DN 146:41897
TI Synergic combinations comprising a styrylquinoline compound and other HIV
infection therapeutic agents
IN Leh, Herve; Zouhiri, Fatima; Mouscadet, Jean-Francois; Thomas,
Claire-Marie
PA Bioalliance Pharma, Fr.; Centre National De La Recherche Scientifique
(C.N.R.S); Ecole Normale Superieure De Cachan; Universite De Paris 11 -
Paris Sud
SO PCT Int. Appl., 57pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006129134	A1	20061207	WO 2005-IB1538	20050601
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI WO 2005-IB1538 20050601

OS MARPAT 146:41897

IT 500287-72-9, TMC-278


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(synergic combinations comprising styrylquinoline compound and other HIV
infection therapeutic agents)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

10/523,753RCE

L4 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1256680 CAPLUS

DN 146:20278

TI 2,4-Pyrimidinediamine compound JAK kinase inhibitors, and their therapeutic use

IN Wong, Brian

PA Rigel Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 26pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006270694	A1	20061130	US 2006-416652	20060502
	WO 2007027238	A2	20070308	WO 2006-US17008	20060502
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-678241P P 20050503

IT 575475-58-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(pyrimidinediamine compound JAK kinase inhibitors, and therapeutic use)

RN 575475-58-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-
(CA INDEX NAME)




10/523,753RCE

L4 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1094952 CAPLUS
DN 145:438608
TI Preparation of pyrazolobenzoxazinylphenylmethanones as HIV viral
replication inhibitors.
IN Tahri, Abdellah; Hu, Lili; Surleraux, Dominique Louis Nestor Ghislain;
Wigerinck, Piet Tom Bert Paul
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 47pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006108828	A1	20061019	WO 2006-EP61499	20060411
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2005-102847	A	20050411		
OS	MARPAT 145:438608				
IT	500287-72-9, Rilpivirine				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combination therapy; preparation of pyrazolobenzoxazinylphenylmethanones as HIV viral replication inhibitors)				
RN	500287-72-9 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)				

Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1065877 CAPLUS
DN 145:389322
TI Intermittent administration of parenteral TMC278 for the prevention of HIV infection
IN Baert, Lieven Elvire Colette; Lewi, Paulus Joannes; Heeres, Jan
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 18pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006106103	A2	20061012	WO 2006-EP61303	20060404
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI EP 2005-102616 A 20050404


IT 500287-72-9, TMC 278

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intermittent administration of parenteral TMC278 for prevention of HIV infection)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



10/523,753RCE

L4 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1001147 CAPLUS
DN 146:219
TI Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside
inhibitors of HIV-1 reverse transcriptase
AU Thakur, Vinay V.; Kim, Joseph T.; Hamilton, Andrew D.; Bailey, Christopher
M.; Domaoal, Robert A.; Wang, Ligong; Anderson, Karen S.; Jorgensen,
William L.
CS Department of Chemistry, Yale University, New Haven, CT, 06520-8107, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5664-5667
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 146:219
IT 500287-72-9, Rilpivirine
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(pyrimidinyl- and triazinyl-amines as inhibitors of HIV-1 reverse
transcriptase)
RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:855447 CAPLUS
DN 145:448644
TI Short-term antiviral activity of TMC278 - a novel NNRTI - in
treatment-naive HIV-1-infected subjects
AU Goebel, Frank; Yakovlev, Alexy; Pozniak, Anton L.; Vinogradova, Elena;
Boogaerts, Griet; Hoetelmans, Richard; de Bethune, Marie-Pierre P.;
Peeters, Monika; Woodfall, Brian
CS Ludwig-Maximilians University, Munich, Germany
SO AIDS (Hagerstown, MD, United States) (2006), 20(13), 1721-1726
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 500287-72-9, TMC 278
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(phase IIa trial of short-term TMC278-C201 showed antiviral activity
and variable pharmacokinetics, was safe and well tolerated by
antiretroviral-naive human immunodeficiency virus-1-infected patient)
RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 . ANSWER 11 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:769016 CAPLUS

DN 145:188904

TI Preparation of HIV inhibiting 2-(4-cyanophenylamino)pyrimidine derivatives

IN Janssen, Paul Adriaan Jan; Heeres, Jan; Lewi, Paulus Joannes; Leemans, Rudolf; Moens, Luc Jozef Raphael

PA Tibotec Pharmaceuticals Ltd., Ire.; Arts, Frank Xavier Jozef Herwig

SO PCT Int. Appl., 34pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006079656	A1	20060803	WO 2006-EP50490	20060127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-100521	A	20050127		
OS	MARPAT 145:188904				
IT	903593-73-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of HIV inhibiting 2-(4-cyanophenylamino)pyrimidine derivs.)				
RN	903593-73-7	CAPLUS			
CN	Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)				



IT 903593-76-0P 903593-77-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of HIV inhibiting 2-(4-cyanophenylamino)pyrimidine derivs.)

RN 903593-76-0 CAPLUS

CN Benzonitrile, 4-[[6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-


10/523,753RCE

3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 903593-77-1 CAPLUS

CN Benzonitrile, 4-[[6-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:494357 CAPLUS

DN 144:495389

TI Compositions comprising salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

IN Guillemont, Jerome Emile Georges; Stevens, Paul Theodoor Agnes; Copmans, Alex Herman; Peeters, Jozef; Stappers, Alfred Elisabeth; Vandecruys, Roger Petrus Gerebern; Stoffels, Paul

PA Fr.

SO U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 485,636.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006111379	A1	20060525	US 2005-219163	20050902
	WO 2003016306	A1	20030227	WO 2002-EP8953	20020809
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004198739	A1	20041007	US 2004-485636	20040203
	US 7125879	B2	20061024		
	ZA 2004001159	A	20050512	ZA 2004-1159	20040212
	WO 2005021001	A1	20050310	WO 2004-EP52028	20040903
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	EP 2001-203090	A	20010813		
	EP 2002-77748	A	20020610		
	WO 2002-EP8953	W	20020809		
	EP 2003-103275	A	20030903		
	EP 2003-103319	A	20030908		
	EP 2003-103335	A	20030910		
	EP 2003-103668	A	20031002		
	US 2004-485636	A2	20040203		
	MY 2004-3578	A	20040902		
	WO 2004-EP52028	A	20040903		
	EP 2005-101467	A	20050225		
	US 2003-499771P	P	20030903		
	US 2003-508486P	P	20031003		

IT 700361-47-3P


RL: PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(compns. comprising (cyanoethenyl)dimethylphenylaminopyrimidinylamino]b

10/523,753RCE

enzonitrile)
RN 700361-47-3 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

IT 500287-72-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(comps. comprising (cyanoethenyl)dimethylphenylaminopyrimidinylamino]benzonitrile)
RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



10/523,753RCE

L4 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:411903 CAPLUS
DN 144:450727
TI Preparation of HIV inhibiting bicyclic pyrimidine derivatives
IN Janssen, Paul Adriaan Jan; Guillemont, Jerome Emile Georges; Paugam, Mikaeel; Delest, Bruno Francois Marie; Heeres, Jan; Lewi, Paulus Joannes
PA Tibotec Pharmaceuticals Ltd., Ire.; Arts, Frank Xavier Jozef Herwig
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006045828	A1	20060504	WO 2005-EP55589	20051027
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005298637	A1	20060504	AU 2005-298637	20051027
	CA 2577588	A1	20060504	CA 2005-2577588	20051027
PRAI	EP 2004-105419	A	20041029		
	WO 2005-EP55589	W	20051027		

OS MARPAT 144:450727


IT 882054-57-1P 882054-58-2P 885453-55-4P
885453-56-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of HIV inhibiting bicyclic pyrimidine derivs.)


RN 882054-57-1 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882054-58-2 CAPLUS

CN Benzonitrile, 4-[[5-amino-4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 885453-55-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 885453-56-5 CAPLUS

CN Benzonitrile, 4-[[5-amino-4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/523,753RCE

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:318550 CAPLUS
 DN 144:370117
 TI Preparation of HIV inhibiting 5-heterocyclyl pyrimidines
 IN Guillemont, Jerome Emile Georges; Heeres, Jan; Lewi, Paulus Joannes
 PA Tibotec Pharmaceuticals Ltd., Ire.
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006035067	A2	20060406	WO 2005-EP54930	20050929
	WO 2006035067	A3	20060824		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005288864	A1	20060406	AU 2005-288864	20050929
	CA 2577467	A1	20060406	CA 2005-2577467	20050929
PRAI	EP 2004-104812	A	20040930		
	WO 2005-EP54930	W	20050929		

OS CASREACT 144:370117; MARPAT 144:370117


IT 882054-28-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of HIV inhibiting 5-heterocyclyl pyrimidines)

RN 882054-28-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(2-furanyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 882054-26-4P 882054-27-5P 882054-29-7P

10/523,753RCE

882054-30-0P 882054-31-1P 882054-32-2P
882054-34-4P 882054-35-5P 882054-36-6P
882054-37-7P 882054-38-8P 882054-39-9P
882054-40-2P 882054-41-3P 882054-42-4P
882054-43-5P 882054-44-6P 882054-45-7P
882054-46-8P 882054-47-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of HIV inhibiting 5-heterocyclyl pyrimidines)

RN 882054-26-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(1H-pyrrol-1-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-27-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-29-7 CAPLUS


CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-5-(1H-pyrrol-1-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE



RN 882054-30-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882054-31-1 CAPLUS

CN Benzonitrile, 4-[[5-(4-amino-3-pyridinyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-32-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(2-thienyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-34-4 CAPLUS

CN Benzonitrile, 4-[[5-(2-benzofuranyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-35-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(3-furanyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-36-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(3-thienyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-37-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(3-quinolinyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-38-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(4-pyridinyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/523,753RCE



RN 882054-39-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882054-40-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-41-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[3-(2-furanyl)-1,2,4-oxadiazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-42-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-43-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[3-(2-thienyl)-1,2,4-oxadiazol-5-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-44-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(2-thiazolyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-45-7 CAPLUS

CN Benzonitrile, 4-[[5-(2-amino-5-thiazolyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-46-8 CAPLUS

CN Benzonitrile, 4-[[5-(3-amino-2-pyridinyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/523,753RCE



RN 882054-47-9 CAPLUS

CN 3-Pyridinecarboxamide, 5-[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 500287-72-9 882054-60-6


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of HIV inhibiting 5-heterocyclyl pyrimidines)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.

10/523,753RCE



RN 882054-60-6 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 882054-49-1P 882054-50-4P 882054-51-5P

882054-52-6P 882054-54-8P 882054-55-9P

882054-57-1P 882054-58-2P 882054-59-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of HIV inhibiting 5-heterocyclyl pyrimidines)

RN 882054-49-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-50-4 CAPLUS


CN Benzonitrile, 4-[[5-chloro-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 882054-51-5 CAPLUS

CN Benzonitrile, 4-[[5-bromo-4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882054-52-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-iodo-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 882054-54-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-55-9 CAPLUS

CN Benzonitrile, 4-[[5-amino-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-57-1 CAPLUS


10/523,753RCE

CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 882054-58-2 CAPLUS

CN Benzonitrile, 4-[[5-amino-4-[[2-chloro-4-(2-cyanoethenyl)-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 882054-59-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/523,753RCE



10/523,753RCE


L4 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:318326 CAPLUS
DN 144:370115
TI Preparation of HIV-inhibiting 5-substituted pyrimidines
IN Guillemont, Jerome Emile Georges; Heeres, Jan; Lewi, Paulus Joannes
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006035069	A1	20060406	WO 2005-EP54932	20050929
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005288866	A1	20060406	AU 2005-288866	20050929
	CA 2575472	A1	20060406	CA 2005-2575472	20050929
PRAI	EP 2004-104805	A	20040930		
	WO 2005-EP54932	W	20050929		
OS	CASREACT 144:370115; MARPAT 144:370115				
IT	882187-65-7P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (in the preparation of HIV-inhibiting 5-substituted pyrimidines)				
RN	882187-65-7 CAPLUS				
CN	Benzonitrile, 4-[[5-(2-chlorophenyl)-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



IT 500287-72-9 882187-05-5


10/523,753RCE

RL: RCT (Reactant); RACT (Reactant or reagent)
(in the preparation of HIV-inhibiting 5-substituted pyrimidines)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-05-5 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 882054-49-1P 882054-50-4P 882054-52-6P

882054-54-8P 882054-55-9P 882054-59-3P

882186-98-3P 882187-00-0P 882187-01-1P

882187-59-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(in the preparation of HIV-inhibiting 5-substituted pyrimidines)

RN 882054-49-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-50-4 CAPLUS

CN Benzonitrile, 4-[[5-chloro-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-52-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-iodo-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-54-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 882054-55-9 CAPLUS

CN Benzonitrile, 4-[[[5-amino-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-59-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/523,753RCE

RN 882186-98-3 CAPLUS

CN Benzonitrile, 4-[[5-bromo-4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-00-0 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882187-01-1 CAPLUS

CN Benzonitrile, 4-[[5-amino-4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882187-59-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 882187-02-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of HIV-inhibiting 5-substituted pyrimidines)

RN 882187-02-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-formyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 882187-04-4P 882187-60-2P 882187-61-3P
 882187-62-4P 882187-63-5P 882187-64-6P
 882187-67-9P 882187-68-0P 882187-71-5P
 882187-72-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of HIV-inhibiting 5-substituted pyrimidines)

RN 882187-04-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-
 [(hydroxyimino)methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 882187-60-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-
 dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N-propyl- (9CI) (CA INDEX
 NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882187-61-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-62-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(dimethylamino)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882187-63-5 CAPLUS

10/523,753RCE

CN Formamide, N-[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-64-6 CAPLUS

CN Acetamide, N-[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882187-67-9 CAPLUS

CN Formamide, N-[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882187-68-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(methoxyimino)methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 882187-71-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/523,753RCE

RN 882187-72-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-[(4-cyanophenyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:317260 CAPLUS

DN 144:370113

TI Preparation of HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines

IN Guillemont, Jerome Emile Georges; Heeres, Jan; Lewi, Paulus Joannes

PA Tibotec Pharmaceuticals Ltd., Ire.

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006035068	A2	20060406	WO 2005-EP54931	20050929
	WO 2006035068	A3	20060831		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005288865	A1	20060406	AU 2005-288865	20050929
	CA 2573976	A1	20060406	CA 2005-2573976	20050929
PRAI	EP 2004-104814	A	20040930		
	WO 2005-EP54931	W	20050929		
OS	CASREACT 144:370113; MARPAT 144:370113				
IT	882186-08-5P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines)				
RN	882186-08-5 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(1,2,3-thiadiazol-4-ylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)				

Double bond geometry as shown.



IT 882186-09-6P 882186-10-9P 882186-11-0P
 882186-12-1P 882186-13-2P 882186-14-3P
 882186-15-4P 882186-16-5P 882186-17-6P
 882186-18-7P 882186-19-8P 882186-20-1P
 882186-21-2P 882186-22-3P 882186-23-4P
 882186-24-5P 882186-25-6P 882186-26-7P
 882186-27-8P 882186-28-9P 882186-29-0P
 882186-30-3P 882186-31-4P 882186-32-5P
 882186-33-6P 882186-34-7P 882186-35-8P
 882186-36-9P 882186-37-0P 882186-38-1P
 882186-39-2P 882186-40-5P 882186-41-6P
 882186-42-7P 882186-43-8P 882186-44-9P
 882186-45-0P 882186-46-1P 882186-47-2P
 882186-48-3P 882186-49-4P 882186-51-8P
 882186-52-9P 882186-53-0P 882186-54-1P
 882186-55-2P 882186-56-3P 882186-57-4P
 882186-58-5P 882186-59-6P 882186-60-9P
 882186-61-0P 882186-62-1P 882186-63-2P
 882186-64-3P 882186-65-4P 882186-66-5P
 882186-67-6P 882186-68-7P 882186-69-8P
 882186-70-1P 882186-71-2P 882186-72-3P
 882186-74-5P 882186-75-6P 882186-76-7P
 882186-77-8P 882186-78-9P 882186-79-0P
 882186-80-3P 882186-81-4P 882186-82-5P
 882186-83-6P 882186-84-7P 882186-85-8P
 882186-87-0P 882186-88-1P 882186-89-2P
 882186-90-5P 882186-91-6P 882186-92-7P
 882186-93-8P 882186-94-9P 882186-95-0P
 882186-96-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of HIV inhibiting 5-carbo- or heterocyclic substituted
 pyrimidines)

RN 882186-09-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-
 [(3-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-10-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(2-furanylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-11-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(3-furanylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-12-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-methoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-13-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-(hydroxymethyl)-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-14-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-15-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-(2-fluorophenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-16-5 CAPLUS

CN Benzonitrile, 4-[[5-[[(6-bromo-2-pyridinyl)methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-17-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(phenylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-18-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-19-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(2-thienylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-20-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2,6-dimethoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-21-2 CAPLUS

CN Benzonitrile, 4-[[5-[[2-chlorophenyl)methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-22-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-methylphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-23-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-methyl-1H-imidazol-4-yl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-24-5 CAPLUS

CN Benzonitrile, 4-[[5-[[[(5-chloro-2-furanyl)methyl]amino]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-2-cyanoethenyl] (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-25-6 CAPLUS

CN Benzonitrile, 4-[[5-[[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-2-cyanoethenyl] (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-26-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-methyl-2-thienyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-27-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-ethyl-2-thienyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-28-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(1H-imidazol-2-ylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-29-0 CAPLUS

CN Benzonitrile, 4-[[5-[[5-bromo-2-furanyl)methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-30-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-phenoxy-3-pyridinyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-31-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[6-(4-morpholinyl)-3-pyridinyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-32-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-33-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[3-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-34-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[4-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 882186-35-8 CAPLUS

CN Benzonitrile, 4-[[5-[[[5-(3-chlorophenyl)-2-furanyl]methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-36-9 CAPLUS

CN Benzonitrile, 4-[[5-[[4-(4-chlorophenyl)methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) . (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-37-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-(4-chlorophenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-38-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[4-(phenylmethoxy)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-39-2 CAPLUS

CN Benzonitrile, 4-[[5-[[[5-(4-bromophenyl)-2-furanyl]methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



/


Br

RN 882186-40-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-
[[3-phenoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX
NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-41-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-(2-thienyl)-3-isoxazolyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 882186-42-7 CAPLUS

CN Benzonitrile, 4-[[5-[[5-(4-chlorophenyl)-2-furanyl]methyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 882186-43-8 CAPLUS

CN Benzonitrile, 4-[[5-[(2-benzofuranylmethyl)amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/523,753RCE

RN 882186-44-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[4-phenoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-45-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-(2,4-dichlorophenyl)-2-furanyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-46-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[4-phenyl-2-thienyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-47-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-methyl-3-phenyl-4-isoxazolyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-48-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[5-phenyl-2-thienyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-49-4 CAPLUS

CN Benzonitrile, 4-[[5-[(2,1,3-benzothiadiazol-5-ylmethyl)amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-51-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-52-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[1,3-dimethyl-1H-pyrazol-5-yl)methyl]amino]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 882186-53-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[1-methyl-1H-imidazol-5-yl)methyl]amino]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-54-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(5-thiazolylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-55-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(2-thiazolylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-56-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[1-methyl-1H-pyrrol-2-yl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-57-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2,4-dimethyl-5-thiazolyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-58-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(4-thiazolylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-59-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-thiazolylmethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-60-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[2-(phenylmethoxy)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-61-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[2-(ethoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-62-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-ethylphenyl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-63-2 CAPLUS

CN Benzonitrile, 4-[[5-[[[1,1'-biphenyl]-2-ylmethyl]amino]-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-64-3 CAPLUS

CN Benzonitrile, 2-[[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-65-4 CAPLUS

CN Benzonitrile, 4-[[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[2-(pyridinylmethyl)amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-66-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[(5-methyl-2-furanyl)methyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 882186-67-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[4-pyridinylmethyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-68-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-furanylmethyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-69-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[3-pyridinylmethyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-70-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-(thienylmethyl)amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-71-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-(2-pyridinyl)ethyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown:


10/523,753RCE



RN 882186-72-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-phenylethyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-74-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-(2-thienyl)ethyl]amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 882186-75-6 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A






RN 882186-76-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[(3-phenylpropyl)amino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-77-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(phenoxyimino)methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 882186-78-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-

10/523,753RCE

[[(phenylmethoxy)imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 882186-79-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[(2-pyridinylmethoxy)imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 882186-80-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl]methoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.


10/523,753RCE



RN 882186-81-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[4-(thiazolylmethoxy)imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 882186-82-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[(2-methyl-4-thiazolyl)methoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.


10/523,753RCE



RN 882186-83-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[(5-methyl-3-isoxazolyl)methoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 882186-84-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[5-[3-(trifluoromethyl)phenyl]-3-isoxazolyl]methoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 882186-85-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[5-(2-methoxyphenyl)-3-isoxazolyl]methoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 882186-87-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methoxy]imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



RN 882186-88-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[4-(4-pyridinylmethoxy)imino]methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 882186-89-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[methyl(1,2,3-thiadiazol-4-ylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-90-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[methyl(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-91-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[2-(2-methoxyphenyl)-2-propenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-92-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[(2E)-3-phenyl-2-propenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882186-93-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[(2E)-3-(2-furanyl)-2-propenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882186-94-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[(2E)-3-(3-furanyl)-2-propenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-95-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[[(2E)-3-(2-thienyl)-2-propenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882186-96-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(phenylamino)methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 500287-72-9 882187-05-5


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882187-05-5 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 882054-49-1P 882054-50-4P 882054-54-8P
882054-55-9P 882186-98-3P 882187-00-0P
882187-01-1P 882187-02-2P 882187-03-3P
882187-04-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of HIV inhibiting 5-carbo- or heterocyclic substituted
pyrimidines)

RN 882054-49-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882054-50-4 CAPLUS

CN Benzonitrile, 4-[[5-chloro-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882054-54-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882054-55-9 CAPLUS

CN Benzonitrile, 4-[[5-amino-4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 882186-98-3 CAPLUS

CN Benzonitrile, 4-[[5-bromo-4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-00-0 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882187-01-1 CAPLUS

10/523,753RCE

CN Benzonitrile, 4-[[5-amino-4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-fluorophenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 882187-02-2 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-formyl-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 882187-03-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-(hydroxymethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 882187-04-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-5-[(hydroxyimino)methyl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




L4 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:212395 CAPLUS
 DN 144:280597
 TI Pharmaceutical compositions containing 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile hydrochloride
 IN Stevens, Paul Theodoor Agnes; Peeters, Jozef; Vandecruys, Roger Petrus Gerebern; Stappers, Alfred Elisabeth; Copmans, Alex Herman
 PA Janssen Pharmaceutica N. V., Belg.; Tibotec Pharmaceuticals Ltd.
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006024668	A1	20060309	WO 2005-EP54342	20050902
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2005021001	A1	20050310	WO 2004-EP52028	20040903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2577288	A1	20060309	CA 2005-2577288	20050902
PRAI	MY 2004-3578	A	20040902		
	WO 2004-EP52028	A	20040903		
	EP 2005-101467	A	20050225		
	EP 2003-103275	A	20030903		
	US 2003-499771P	P	20030903		
	EP 2003-103319	A	20030908		
	EP 2003-103335	A	20030910		
	EP 2003-103668	A	20031002		
	US 2003-508486P	P	20031003		
	WO 2005-EP54342	W	20050902		
IT	500287-72-9P				
	RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(pharmaceutical compns. containing cyanoethenyl dimethylphenylaminopyrimidin ylbzonitrile derivative)				
RN	500287-72-9 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)				

10/523,753RCE

Double bond geometry as shown.




IT 700361-47-3P

RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. containing cyanoethenyldimethylphenylaminopyrimidinylbenzonitrile derivative)

RN 700361-47-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:212394 CAPLUS

DN 144:280596

TI Tablets containing fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile

IN Stevens, Paul Theodoor Agnes; Peeters, Jozef; Vandecruys, Roger Petrus Gerebern; Stappers, Alfred Elisabeth; Copmans, Alex Herman

PA Janssen Pharmaceutica N. V., Belg.; Tibotec Pharmaceuticals Ltd.

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006024667	A1	20060309	WO 2005-EP54341	20050902
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2005021001	A1	20050310	WO 2004-EP52028	20040903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2577273	A1	20060309	CA 2005-2577273	20050902

PRAI MY 2004-3578 A 20040902

WO 2004-EP52028 A 20040903

EP 2005-101447 A 20050225

EP 2003-103275 A 20030903

US 2003-499771P P 20030903

EP 2003-103319 A 20030908

EP 2003-103335 A 20030910

EP 2003-103668 A 20031002

US 2003-508486P P 20031003

WO 2005-EP54341 W 20050902

IT 877817-88-4P

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (tablets containing fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile)

RN 877817-88-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


10/523,753RCE

CM 1

CRN 500287-72-9

CMF C22 H18 N6

Double bond geometry as shown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



IT 500287-72-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(tablets containing fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1341982 CAPLUS
DN 144:142011
TI Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase
AU Jorgensen, William L.; Ruiz-Caro, Juliana; Tirado-Rives, Julian; Basavapathruni, Aravind; Anderson, Karen S.; Hamilton, Andrew D.
CS Department of Chemistry, Yale University, New Haven, CT, 06520-8107, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(3), 663-667
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
IT 500287-72-9, Rilpivirine
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase)
RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:216682 CAPLUS

DN 142:273973

TI Combinations of pyrimidine-containing nonnucleoside reverse transcriptase inhibitor (NNRTI) TMC278 with reverse transcriptase inhibitors for the treatment of HIV infection

IN Stoffels, Paul

PA Tibotec Pharmaceuticals Ltd., Ire.

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005021001	A1	20050310	WO 2004-EP52028	20040903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004268390	A1	20050310	AU 2004-268390	20040903
	CA 2537095	A1	20050310	CA 2004-2537095	20040903
	EP 1663240	A1	20060607	EP 2004-787096	20040903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004014027	A	20061024	BR 2004-14027	20040903
	EP 1632232	A1	20060308	EP 2005-108086	20050902
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CA 2577273	A1	20060309	CA 2005-2577273	20050902
	CA 2577288	A1	20060309	CA 2005-2577288	20050902
	WO 2006024667	A1	20060309	WO 2005-EP54341	20050902
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2006024668	A1	20060309	WO 2005-EP54342	20050902
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

10/523,753RCE

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

	US 2006111379	A1	20060525	US 2005-219163	20050902
	NO 2006001374	A	20060327	NO 2006-1374	20060327
PRAI	EP 2003-103275	A	20030903		
	US 2003-499771P	P	20030903		
	EP 2003-103319	A	20030908		
	EP 2003-103335	A	20030910		
	EP 2003-103668	A	20031002		
	US 2003-508486P	P	20031003		
	EP 2001-203090	A	20010813		
	EP 2002-77748	A	20020610		
	WO 2002-EP8953	W	20020809		
	US 2004-485636	A2	20040203		
	MY 2004-3578	A	20040902		
	WO 2004-EP52028	W	20040903		
	EP 2005-101447	A	20050225		
	EP 2005-101467	A	20050225		
	EP 2005-108086	A	20050902		
	WO 2005-EP54341	W	20050902		
	WO 2005-EP54342	W	20050902		
IT	500287-72-9				
	RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pyrimidine-containing nonnucleoside reverse transcriptase inhibitor TMC278 combination with nucleoside/nucleotide reverse transcriptase inhibitor for treatment of HIV infection)				
RN	500287-72-9	CAPLUS			
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]- (CA INDEX NAME)				

Double bond geometry as shown.




IT 500287-94-5 620622-82-4 620622-82-4D,
stereoisomers and prodrugs 847445-98-1 847445-99-2
847446-00-8 847446-01-9 847446-02-0
847446-03-1 847446-04-2 847446-05-3
847446-06-4 847446-07-5 847446-08-6
847446-09-7 847446-10-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pyrimidine-containing nonnucleoside reverse transcriptase inhibitor TMC278
combination with nucleoside/nucleotide reverse transcriptase inhibitor
for treatment of HIV infection)

10/523,753RCE

RN 500287-94-5 CAPLUS


CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 620622-82-4 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 620622-82-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 847445-98-1 CAPLUS

CN Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-, mixt. with 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

CMF C22 H18 N6




CM 2

CRN 147127-20-6

CMF C9 H14 N5 O4 P

Absolute stereochemistry. Rotation (+).



10/523,753RCE


RN 847445-99-2 CAPLUS

CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-, bis(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1), mixt. with 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

CMF C22 H18 N6



CM 2

CRN 202138-50-9


CMF C19 H30 N5 O10 P . C4 H4 O4

CM 3

CRN 201341-05-1

CMF C19 H30 N5 O10 P

Absolute stereochemistry.




CM 4

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.


10/523,753RCE



RN 847446-00-8 CAPLUS
CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, mixt. with 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

CM 1


CRN 620622-82-4
CMF C22 H18 N6



CM 2

CRN 143491-57-0
CMF C8 H10 F N3 O3 S

Absolute stereochemistry. Rotation (-).




RN 847446-01-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, mixt. with rel-4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

10/523,753RCE

CMF C22 H18 N6




CM 2

CRN 143491-54-7

CMF C8 H10 F N3 O3 S

Relative stereochemistry.



RN 847446-02-0 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, mixt. with 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

CMF C22 H18 N6

10/523,753RCE




CM 2

CRN 134678-17-4

CMF C8 H11 N3 O3 S

Absolute stereochemistry. Rotation (-).




RN 847446-03-1 CAPLUS

Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-, mixt. with 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone and 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

CMF C22 H18 N6




10/523,753RCE

CM 2

CRN 147127-20-6
CMF C9 H14 N5 O4 P


Absolute stereochemistry. Rotation (+).



CM 3

CRN 134678-17-4
CMF C8 H11 N3 O3 S

Absolute stereochemistry. Rotation (-).




RN 847446-04-2 CAPLUS

CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-, bis(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1), mixt. with 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone and 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4
CMF C22 H18 N6


10/523,753RCE



CM 2

CRN 134678-17-4
CMF C8 H11 N3 O3 S

Absolute stereochemistry. Rotation (-).




CM 3

CRN 202138-50-9
CMF C19 H30 N5 O10 P . C4 H4 O4

CM 4

CRN 201341-05-1
CMF C19 H30 N5 O10 P

Absolute stereochemistry.




CM 5

10/523,753RCE

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 847446-05-3 CAPLUS
CN Phosphonic acid, [[[1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-, mixt. with (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (9CI) (CA INDEX NAME)

CM 1


CRN 620622-82-4
CMF C22 H18 N6



CM 2

CRN 147127-20-6
CMF C9 H14 N5 O4 P

Absolute stereochemistry. Rotation (+).




CM 3

CRN 136470-78-5
CMF C14 H18 N6 O

10/523,753RCE

Absolute stereochemistry. Rotation (-).




RN 847446-06-4 CAPLUS

CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl]-, bis(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1), mixt. with (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

CMF C22 H18 N6




CM 2

CRN 136470-78-5

CMF C14 H18 N6 O

Absolute stereochemistry. Rotation (-).

10/523,753RCE



CM 3

CRN 202138-50-9


CMF C19 H30 N5 O10 P . C4 H4 O4

CM 4

CRN 201341-05-1

CMF C19 H30 N5 O10 P

Absolute stereochemistry.




CM 5

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 847446-07-5 CAPLUS


CN Benzonitrile, 4-[[4-[(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, mixt. with 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone and 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

10/523,753RCE

CMF C22 H18 N6




CM 2

CRN 143491-57-0

CMF C8 H10 F N3 O3 S

Absolute stereochemistry. Rotation (-).




CM 3

CRN 134678-17-4

CMF C8 H11 N3 O3 S

Absolute stereochemistry. Rotation (-).



RN 847446-08-6 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, mixt. with (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

10/523,753RCE

CM 1

CRN 620622-82-4

CMF C22 H18 N6




CM 2

CRN 143491-57-0

CMF C8 H10 F N3 O3 S

Absolute stereochemistry. Rotation (-).




CM 3

CRN 136470-78-5

CMF C14 H18 N6 O

Absolute stereochemistry. Rotation (-).

10/523,753RCE




RN 847446-09-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-, mixt. with (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone (9CI) (CA INDEX NAME)

CM 1

CRN 620622-82-4

CMF C22 H18 N6




CM 2

CRN 136470-78-5

CMF C14 H18 N6 O

Absolute stereochemistry. Rotation (-).

10/523,753RCE




CM 3

CRN 134678-17-4

CMF C8 H11 N3 O3 S

Absolute stereochemistry. Rotation (-).



RN 847446-10-0 CAPLUS

CN 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, bis(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1), mixt. with 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone and 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile monohydrochloride (9CI) (CA INDEX NAME)


CM 1

CRN 700361-47-3

CMF C22 H18 N6 . Cl H

Double bond geometry as shown.

10/523,753RCE




● HCl

CM 2

CRN 143491-57-0

CMF C8 H10 F N3 O3 S

Absolute stereochemistry. Rotation (-).



CM 3

CRN 202138-50-9

CMF C19 H30 N5 O10 P . C4 H4 O4


CM 4

CRN 201341-05-1

CMF C19 H30 N5 O10 P

Absolute stereochemistry.

10/523,753RCE




CM 5

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/523,753RCE

L4 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:164968 CAPLUS
DN 142:416993
TI Concentration and pH dependent aggregation of hydrophobic drug molecules
and relevance to oral bioavailability
AU Frenkel, Yulia Volovik; Clark, Arthur D., Jr.; Das, Kalyan; Wang, Yuh-Hwa;
Lewi, Paul J.; Janssen, Paul A. J.; Arnold, Eddy
CS Center for Advanced Biotechnology and Medicine and Department of Chemistry
and Chemical Biology, Rutgers University, Piscataway, NJ, 08854, USA
SO Journal of Medicinal Chemistry (2005), 48(6), 1974-1983
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 244767-86-0, R 152929 500287-72-9, R 278474
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); PRP
(Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(concentration and pH dependent aggregation of hydrophobic non-nucleoside
reverse transcriptase inhibitor drugs and relevance to their oral
bioavailability)
RN 244767-86-0 CAPLUS
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-
dimethyl- (CA INDEX NAME)



RN 500287-72-9 CAPLUS
CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



10/523,753RCE

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:997144 CAPLUS

DN 142:190188

TI Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds

AU Lewi, Paul; Arnold, Eddy; Andries, Koen; Bohets, Hilde; Borghys, Herman; Clark, Arthur; Daeyaert, Frits; Das, Kalyan; de Bethune, Marie-Pierre; de Jonge, Marc; Heeres, Jan; Koymans, Luc; Leempoels, Jos; Peeters, Jef; Timmerman, Philip; Van den Broeck, Walter; Vanhoutte, Frederic; van't Klooster, Gerben; Vinkers, Maarten; Volovik, Yulia; Janssen, Paul A. J.

CS Center for Molecular Design (CMD), Janseen Pharmaceutica, Vosselaar, Belg.

SO Drugs in R&D (2004), 5(5), 245-257

CODEN: DRDDFD; ISSN: 1174-5886

PB Adis International Ltd.

DT Journal

LA English

IT 244767-86-0


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(AUC, transepithelial transport, ionizability, lipophilicity, aggregate radius, antiviral activity of HIV-1 NNRTIs of diaryltriazine and diarylpyrimidine classes, showed good correlation with each other in dog, rat and human)

RN 244767-86-0 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:985555 CAPLUS
 DN 142:219230
 TI Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1
 AU Guillemont, Jerome; Pasquier, Elisabeth; Palandjian, Patrice; Vernier, Daniel; Gaurrand, Sandrine; Lewi, Paul J.; Heeres, Jan; de Jonge, Marc R.; Koymans, Lucien M. H.; Daeyaert, Frits F. D.; Vinkers, Maarten H.; Arnold, Edward; Das, Kalyan; Pauwels, Rudi; Andries, Koen; de Bethune, Marie-Pierre; Bettens, Eva; Hertogs, Kurt; Wigerinck, Piet; Timmerman, Philip; Janssen, Paul A. J.
 CS Medicinal Chemistry Department, Johnson Johnson Pharmaceutical Research and Development, Val de Reuil, Fr.
 SO Journal of Medicinal Chemistry (2005), 48(6), 2072-2079
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:219230
 IT 500287-72-9P 500287-94-5P 500287-96-7P
 500287-98-9P 500288-00-6P 823786-24-9P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (stereoselective preparation, antiviral activity against HIV-1, and structure-activity relationship of di(arylamino)pyrimidines using amination of (cyanophenylamino)chloropyrimidine with anilines and stereoselective olefination as the key step)
 RN 500287-72-9 CAPLUS
 CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 500287-94-5 CAPLUS
 CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500287-96-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500287-98-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500288-00-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 823786-24-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-chloro-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 500290-59-5P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stereoselective preparation, antiviral activity against HIV-1, and structure-activity relationship of di(arylaminopyrimidines using amination of (cyanophenylamino)chloropyrimidine with anilines and stereoselective olefination as the key step)

RN 500290-59-5 CAPLUS

CN Butanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/523,753RCE



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:937131 CAPLUS

DN 142:211167

TI In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)

AU Janssen, Paul A. J.; Lewi, Paul J.; Arnold, Eddy; Daeyaert, Frits; de Jonge, Marc; Heeres, Jan; Koymans, Luc; Vinkers, Maarten; Guillemont, Jerome; Pasquier, Elisabeth; Kukla, Mike; Ludovici, Don; Andries, Koen; de Bethune, Marie-Pierre; Pauwels, Rudi; Das, Kalyan; Clark, Art D., Jr.; Frenkel, Yulia Volovik; Hughes, Stephen H.; Medaer, Bart; De Knaep, Fons; Bohets, Hilde; De Clerck, Fred; Lampo, Ann; Williams, Peter; Stoffels, Paul

CS Center for Molecular Design, Janssen Pharmaceutica, Vosselaar, B-2350,
Belg.

SO Journal of Medicinal Chemistry (2005), 48(6), 1901-1909
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal; General Review

LA English


IT 500287-72-9, Rilpivirine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery of novel anti-HIV drug rilpivirine)

RN 500287-72-9 CAPLUS


CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:848303 CAPLUS
 DN 142:285
 TI A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides
 AU van Herrewege, Yven; Vanham, Guido; Michiels, Jo; Fransen, Katrien; Kestens, Luc; Andries, Koen; Janssen, Paul; Lewi, Paul
 CS HIV Virology Research Unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belg.
 SO Antimicrobial Agents and Chemotherapy (2004), 48(10), 3684-3689
 CODEN: AMACCQ; ISSN: 0066-4804
 PB American Society for Microbiology
 DT Journal
 LA English
 IT 244767-86-0, R 152929 500287-72-9, R 278474
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with anti-AIDS applications)
 RN 244767-86-0 CAPLUS
 CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)



RN 500287-72-9 CAPLUS
 CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.



10/523,753RCE

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:675730 CAPLUS
 DN 141:207218
 TI Pyrimidine derivatives for the prevention of HIV infection
 IN Janssen, Paul Adriaan Jan; Heeres, Jan; Lewi, Paulus Joannes; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Daeyaert, Frederik Frans Desire; Vinkers, Hendrik Maarten
 PA Janssen Pharmaceutica N.V., Belg.; Arts, Theodora Joanna Francisca; Janssen, Graziella Maria Constantina; Janssen, Herwig Josephus Margareta; Janssen, Jasmine Josee Werner; Janssen, Paul Peter Maria; Janssen, Maroussia Godelieve Frank; Guillemont, Jerome Emile Georges; Pasquier, Elisabeth Therese Jeanne
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004069812	A1	20040819	WO 2004-EP1011	20040204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004210081	A1	20040819	AU 2004-210081	20040204
	CA 2513527	A1	20040819	CA 2004-2513527	20040204
	EP 1597237	A1	20051123	EP 2004-707937	20040204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007329	A	20060110	BR 2004-7329	20040204
	CN 1747937	A	20060315	CN 2004-80003460	20040204
	JP 2006516591	T	20060706	JP 2006-501729	20040204
	IN 2005DN02821	A	20070316	IN 2005-DN2821	20050624
	US 2007021449	A1	20070125	US 2005-544735	20050805
	NO 2005004143	A	20050906	NO 2005-4143	20050906
PRAI	WO 2003-EP1291	A	20030207		
	WO 2003-EP301291	A	20030207		
	WO 2004-EP1011	A	20040204		

OS MARPAT 141:207218

IT 500287-72-9 500287-94-5 500287-96-7
 500287-98-9 500288-04-0 500288-06-2
 500289-17-8 500289-19-0 500289-21-4
 500289-23-6 500289-25-8 500289-27-0
 500289-29-2 500289-30-5 500289-31-6
 500290-61-9 500290-63-1 500290-65-3
 500292-40-0 500292-48-8 500292-52-4
 500292-58-0 500292-62-6 500292-64-8
 500292-68-2 500292-70-6 500292-72-8
 500292-74-0 500292-80-8 620622-82-4
 708254-94-8 708254-95-9 741256-90-6
 741256-91-7 741256-92-8 741257-01-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pyrimidine derivs. for the prevention of HIV infection)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 500287-94-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500287-96-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500287-98-9 CAPLUS

10/523,753RCE


CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500288-04-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[2-cyano-1-(2-furanyl)ethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500288-06-2 CAPLUS


CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-4-fluoro- (9CI) (CA INDEX NAME)



RN 500289-17-8 CAPLUS


CN 2-Thiopheneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 500289-19-0 CAPLUS

CN 1,3-Benzodioxole-5-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)




RN 500289-21-4 CAPLUS

CN 2-Naphthaleneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-23-6 CAPLUS

CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-4-methoxy- (9CI) (CA INDEX NAME)




RN 500289-25-8 CAPLUS

CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-


10/523,753RCE

pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)




RN 500289-27-0 CAPLUS

CN 1H-Pyrrole-2-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-1-methyl- (9CI) (CA INDEX NAME)



RN 500289-29-2 CAPLUS


CN 3-Thiopheneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



10/523,753RCE


RN 500289-30-5 CAPLUS

CN Benzeneacetonitrile, 4-bromo- α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-31-6 CAPLUS


CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-3-methyl- (9CI) (CA INDEX NAME)



RN 500290-61-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-(cyanomethylene)propyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500290-63-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-(cyanomethylene)-2-methylpropyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500290-65-3 CAPLUS


CN Benzonitrile, 4-[[4-[[4-[(1Z)-1-(cyanomethylene)-2-methylpropyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500292-40-0 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyano-1-propenyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500292-48-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 500292-52-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-(2-furanyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500292-58-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10/523,753RCE

RN 500292-62-6 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-[(1E)-2-cyanoethenyl]phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500292-64-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-methoxyphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500292-68-2 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-(2-cyano-1-propenyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


10/523,753RCE



RN 500292-70-6 CAPLUS


CN Benzonitrile, 4-[[4-[[2-bromo-4-[(1E)-2-cyanoethenyl]-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500292-72-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyano-1-propenyl)-2-methoxyphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500292-74-0 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-(2-cyano-1-propenyl)phenyl]amino]-2-

10/523,753RCE


pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500292-80-8 CAPLUS


CN Benzonitrile, 4-[[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 620622-82-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




10/523,753RCE

RN 708254-94-8 CAPLUS

CN Benzonitrile, 4-[[4-[[3-[(1E)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 708254-95-9 CAPLUS

CN Benzonitrile, 4-[[4-[[3-[(1Z)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 741256-90-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyano-1-methylethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


10/523,753RCE



RN 741256-91-7 CAPLUS


CN 2-Propenoic acid, 2-cyano-3-[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]-, 1,1-dimethylethyl ester, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 741256-92-8 CAPLUS

CN Butanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)




RN 741257-01-2 CAPLUS

10/523,753RCE

CN. Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-propenyl]-2-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI). (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:486399 CAPLUS

DN 141:54353

TI Pharmaceutical compositions comprising a surfactant and a physiologically tolerable water-soluble acid respectively base, and a basic respectively acidic drug compound, containing a pyrimidine unit, for treating HIV

IN Vandecruys, Roger Petrus Gerebern

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050068	A1	20040617	WO 2002-EP13558	20021129
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002350719	A1	20040623	AU 2002-350719	20021129
	CA 2505742	A1	20040617	CA 2003-2505742	20031125
	WO 2004050058	A2	20040617	WO 2003-EP50890	20031125
	WO 2004050058	A3	20040930		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003294038	A1	20040623	AU 2003-294038	20031125
	EP 1567134	A2	20050831	EP 2003-789453	20031125
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003016532	A	20051004	BR 2003-16532	20031125
	CN 1720027	A	20060111	CN 2003-80104619	20031125
	JP 2006514635	T	20060511	JP 2004-556332	20031125
	IN 2005DN02185	A	20070302	IN 2005-DN2185	20050524
	US 2006078609	A1	20060413	US 2005-536542	20050526
	NO 2005003143	A	20050627	NO 2005-3143	20050627
PRAI	WO 2002-EP13558	A	20021129		
	WO 2003-EP50890	W	20031125		
IT	500287-72-9P				
	RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(anti-HIV agent; preparation of pyrimidine-based anti-HIV agents and their pharmaceutical compns.)				
RN	500287-72-9 CAPLUS				
CN	Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)				

10/523,753RCE

Double bond geometry as shown.




IT 244767-86-0P 500287-94-5P 500287-96-7P
500287-98-9P 500288-00-6P 500288-04-0P
500288-06-2P 500288-40-4P 500288-43-7P
500288-60-8P 500289-17-8P 500289-19-0P
500289-21-4P 500289-23-6P 500289-25-8P
500289-27-0P 500289-29-2P 500289-30-5P
500289-31-6P 500290-59-5P 500290-61-9P
500290-63-1P 500290-65-3P 500290-85-7P
500292-32-0P 500292-40-0P 500292-48-8P
500292-52-4P 500292-58-0P 500292-62-6P
500292-64-8P 500292-68-2P 500292-70-6P
500292-72-8P 500292-74-0P 500292-80-8P
620622-82-4P 708254-94-8P 708254-95-9P
708254-97-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(anti-HIV agent; preparation of pyrimidine-based anti-HIV agents and their
pharmaceutical comps.)

RN 244767-86-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-
dimethyl- (CA INDEX NAME)




RN 500287-94-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 500287-96-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500287-98-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500288-00-6 CAPLUS

10/523,753RCE


CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500288-04-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[2-cyano-1-(2-furanyl)ethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500288-06-2 CAPLUS

CN Benzeneacetonitrile, α-[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-4-fluoro- (9CI) (CA INDEX NAME)




RN 500288-40-4 CAPLUS

CN Butanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3-(2-furanyl)-5-methylphenyl]methylene]- (9CI) (CA INDEX NAME)




RN 500288-43-7 CAPLUS

CN Propanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500288-60-8 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(1-chloro-2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



10/523,753RCE


RN 500289-17-8 CAPLUS

CN 2-Thiopheneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)




RN 500289-19-0 CAPLUS

CN 1,3-Benzodioxole-5-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-21-4 CAPLUS


CN 2-Naphthaleneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-23-6 CAPLUS


CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-4-methoxy- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 500289-25-8 CAPLUS

CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-27-0 CAPLUS


CN 1H-Pyrrole-2-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-1-methyl- (9CI) (CA INDEX NAME)



RN 500289-29-2 CAPLUS


CN 3-Thiopheneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 500289-30-5 CAPLUS

CN Benzeneacetonitrile, 4-bromo- α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-31-6 CAPLUS

CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-3-methyl- (9CI) (CA INDEX NAME)




RN 500290-59-5 CAPLUS

CN Butanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500290-61-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-(cyanomethylene)propyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500290-63-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-(cyanomethylene)-2-methylpropyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500290-65-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-1-(cyanomethylene)-2-methylpropyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE


Double bond geometry as shown.



RN 500290-85-7 CAPLUS


CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-methyl-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500292-32-0 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyano-1-propenyl)-2-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500292-40-0 CAPLUS

10/523,753RCE


CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyano-1-propenyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500292-48-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500292-52-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-(2-furanyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500292-58-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500292-62-6 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-[(1E)-2-cyanoethenyl]phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500292-64-8 CAPLUS

10/523,753RCE


CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-methoxyphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500292-68-2 CAPLUS


CN Benzonitrile, 4-[[4-[[2-bromo-4-(2-cyano-1-propenyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500292-70-6 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-[(1E)-2-cyanoethenyl]-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



10/523,753RCE


RN 500292-72-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyano-1-propenyl)-2-methoxyphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500292-74-0 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-(2-cyano-1-propenyl)phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500292-80-8 CAPLUS

CN Benzonitrile, 4-[[4-[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/523,753RCE



RN 620622-82-4 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)



RN 708254-94-8 CAPLUS

CN Benzonitrile, 4-[[4-[[3-[(1E)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 708254-95-9 CAPLUS

CN Benzonitrile, 4-[[4-[[3-[(1Z)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)


10/523,753RCE

Double bond geometry as shown.



RN 708254-97-1 CAPLUS

CN 2-Propenoic acid, 2-cyano-3-[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:162661 CAPLUS

DN 140:199342

TI Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

IN Schils, Didier Philippe Robert; Willems, Joannes Josephus Maria; Medaer, Bart Petrus Anna Maria Jozef; Pasquier, Elisabeth Therese Jeanne; Janssen, Paul Adriaan Jan; Heeres, Jan; Leenders, Ruben Gerardus George

PA Janssen Pharmaceutica N.V., Belg.; Guillemont, Jerome Emile Georges

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016581	A1	20040226	WO 2003-EP50366	20030807
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2493794	A1	20040226	CA 2003-2493794	20030807
	AU 2003266413	A1	20040303	AU 2003-266413	20030807
	EP 1529032	A1	20050511	EP 2003-787813	20030807
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003013545	A	20050712	BR 2003-13545	20030807
	CN 1681774	A	20051012	CN 2003-819276	20030807
	JP 2005537303	T	20051208	JP 2004-528518	20030807
	NZ 538611	A	20070330	NZ 2003-538611	20030807
	NO 2005000524	A	20050201	NO 2005-524	20050201
	US 2006167253	A1	20060727	US 2005-523753	20050208
PRAI	EP 2002-78306	A	20020809		
	WO 2003-EP50366	W	20030807		

OS CASREACT 140:199342; MARPAT 140:199342

IT 500287-72-9P 620622-82-4P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)


(processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.

10/523,753RCE



RN 620622-82-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:142963 CAPLUS

DN 140:199334

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor
modulators for treatment of autoimmune diseases

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,
Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar

PA Rigel Pharmaceuticals, USA

SO PCT Int. Appl., 811 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492325	A1	20040219	CA 2003-2492325	20030729
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	CN 1678321	A	20051005	CN 2003-821120	20030729
	JP 2006514989	T	20060518	JP 2005-506142	20030729
	NZ 537752	A	20061222	NZ 2003-537752	20030729
	US 2007060603	A1	20070315	US 2003-631029	20030729
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	US 2005209230	A1	20050922	US 2004-911684	20040803
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	IN 2005KN00302	A	20060421	IN 2005-KN302	20050228
	US 2006025410	A1	20060202	US 2005-149105	20050608
	US 2006035916	A1	20060216	US 2005-148746	20050608
	US 2006058292	A1	20060316	US 2005-149418	20050608
	US 2006135543	A1	20060622	US 2005-299207	20051208
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2003-631029	A	20030729		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US24087	W	20030729		
	US 2004-858343	A3	20040601		
OS	MARPAT 140:199334				
IT	575475-58-0P 575476-12-9P 575476-24-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				

10/523,753RCE

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)


RN 575475-58-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-
(CA INDEX NAME)



RN 575476-12-9 CAPLUS


CN Benzonitrile, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (9CI) (CA INDEX NAME)



RN 575476-24-3 CAPLUS

CN Benzonitrile, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[6-hydroxy-
(9CI) (CA INDEX NAME)

10/523,753RCE



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:913004 CAPLUS
DN 139:374987
TI Microbicidal pyrimidine or triazine compounds for preventing sexual HIV
transmission
IN Van Roey, Jens Marcel; De Bethune, Marie-Pierre T. M. M. G.; Stoffels,
Paul
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2003094920	A1	20031120	WO 2003-EP50158	20030513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003240844	A1	20031111	AU 2003-240844	20030513
	CA 2486078	A1	20031120	CA 2003-2486078	20030513
	BR 2003010021	A	20050215	BR 2003-10021	20030513
	EP 1505980	A1	20050216	EP 2003-730208	20030513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005526846	T	20050908	JP 2004-503005	20030513
	CN 1668305	A	20050914	CN 2003-816359	20030513
	IN 2004DN03779	A	20070112	IN 2004-DN3779	20041130
	NO 2004005267	A	20050214	NO 2004-5267	20041201
	US 2006166943	A1	20060727	US 2005-514361	20050531
PRAI	EP 2002-76897	A	20020513		
	WO 2003-EP50158	W	20030513		

OS MARPAT 139:374987


IT 244767-86-0 244767-86-0D, N-oxide or quaternary amine
derivs. 244767-94-0 244767-94-0D, N-oxide or
quaternary amine derivs. 244768-01-2 244768-01-2D,
N-oxide or quaternary amine derivs. 269055-06-3
269055-06-3D, N-oxide or quaternary amine derivs.
269055-46-1 269055-46-1D, N-oxide or quaternary amine
derivs.

RL: DEV (Device component use); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidine and triazine compds. for preventing sexual HIV
transmission)

RN 244767-86-0 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-
dimethyl- (CA INDEX NAME)

10/523,753RCE




RN 244767-86-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)



RN 244767-94-0 CAPLUS

CN Benzonitrile, 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 244767-94-0 CAPLUS

CN Benzonitrile, 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-


10/523,753RCE

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 244768-01-2 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 244768-01-2 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



10/523,753RCE


RN 269055-06-3 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-06-3 CAPLUS


CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-46-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)

10/523,753RCE



RN 269055-46-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:892834 CAPLUS

DN 139:365764

TI Diblock copolymers for use in pharmaceutical dosage forms

IN Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna;
Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093344	A1	20031113	WO 2003-EP4368	20030424
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2483282	A1	20031113	CA 2003-2483282	20030424
	AU 2003222310	A1	20031117	AU 2003-222310	20030424
	EP 1504047	A1	20050209	EP 2003-717321	20030424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003009688	A	20050222	BR 2003-9688	20030424
	NZ 536294	A	20050527	NZ 2003-536294	20030424
	CN 1649932	A	20050803	CN 2003-809579	20030424
	JP 2005524730	T	20050818	JP 2004-501483	20030424
	ZA 2004008854	A	20051102	ZA 2004-8854	20041102
	NO 2004005283	A	20050107	NO 2004-5283	20041202
	US 2006034797	A1	20060216	US 2005-522456	20050121
PRAI	US 2002-377901P	P	20020503		
	WO 2003-EP4368	W	20030424		


IT 620622-82-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diblock copolymers for use in pharmaceutical dosage forms)

RN 620622-82-4 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:610204 CAPLUS

DN 139:164801

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan; Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 648 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2474277	A1	20030807	CA 2003-2474277	20030131
	US 2004029902	A1	20040212	US 2003-355543	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005516046	T	20050602	JP 2003-563490	20030131
	CN 1625400	A	20050608	CN 2003-803180	20030131
	BR 2003007355	A	20060411	BR 2003-7355	20030131
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	US 2005209230	A1	20050922	US 2004-911684	20040803
	IN 2004KN01139	A	20060512	IN 2004-KN1139	20040809
	NO 2004003632	A	20041026	NO 2004-3632	20040831
	US 2006025410	A1	20060202	US 2005-149105	20050608
	US 2006035916	A1	20060216	US 2005-148746	20050608
	US 2006058292	A1	20060316	US 2005-149418	20050608
	US 2006135543	A1	20060622	US 2005-299207	20051208
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US3022	W	20030131		
	US 2004-858343	A3	20040601		

OS MARPAT 139:164801

IT 575475-58-0P 575476-12-9P 575476-24-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)

10/523,753RCE


RN 575475-58-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-fluoro-4-pyrimidinyl]amino]-
(CA INDEX NAME)




RN 575476-12-9 CAPLUS

CN Benzonitrile, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (9CI) (CA
INDEX NAME)



RN 575476-24-3 CAPLUS

CN Benzonitrile, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis[6-hydroxy-
(9CI) (CA INDEX NAME)



L4 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:154426 CAPLUS

DN 138:205077

TI Preparation of pyrimidines as HIV inhibitors.

IN Guillemont, Jerome Emile Georges; Palandjian, Patrice; De Jonge, Marc
 Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Daeyaert,
 Frederik Frans Desire; Heeres, Jan; Van Aken, Koen Jeanne Alfons; Lewi,
 Paulus Joannes; Janssen, Paul Adriaan Jan

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003016306	A1	20030227	WO 2002-EP8953	20020809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2452217	A1	20030227	CA 2002-2452217	20020809
	AU 2002329238	A1	20030303	AU 2002-329238	20020809
	EP 1419152	A1	20040519	EP 2002-764839	20020809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011909	A	20040824	BR 2002-11909	20020809
	CN 1541215	A	20041027	CN 2002-815920	20020809
	HU 200401346	A2	20041228	HU 2004-1346	20020809
	JP 2005507380	T	20050317	JP 2003-521229	20020809
	NZ 530951	A	20051028	NZ 2002-530951	20020809
	US 2004198739	A1	20041007	US 2004-485636	20040203
	US 7125879	B2	20061024		
	IN 2004DN00265	A	20050401	IN 2004-DN265	20040206
	NO 2004000633	A	20040312	NO 2004-633	20040212
	ZA 2004001159	A	20050512	ZA 2004-1159	20040212
	US 2006111379	A1	20060525	US 2005-219163	20050902
	US 2006252764	A1	20061109	US 2006-474855	20060626
PRAI	EP 2001-203090	A	20010813		
	EP 2002-77748	A	20020610		
	WO 2002-EP8953	W	20020809		
	EP 2003-103275	A	20030903		
	EP 2003-103319	A	20030908		
	EP 2003-103335	A	20030910		
	EP 2003-103668	A	20031002		
	US 2004-485636	A2	20040203		
	MY 2004-3578	A	20040902		
	WO 2004-EP52028	A	20040903		
	EP 2005-101467	A	20050225		
OS	MARPAT 138:205077				
IT	500287-72-9P 500287-94-5P 500287-96-7P				
	500287-98-9P 500288-00-6P 500288-02-8P				
	500288-04-0P 500288-06-2P 500288-08-4P				
	500288-40-4P 500288-43-7P 500288-60-8P				
	500289-17-8P 500289-19-0P 500289-21-4P				

10/523,753RCE

500289-23-6P 500289-25-8P 500289-27-0P
500289-29-2P 500289-30-5P 500289-31-6P
500290-59-5P 500290-61-9P 500290-63-1P
500290-65-3P 500290-85-7P 500292-32-0P
500292-40-0P 500292-48-8P 500292-52-4P
500292-58-0P 500292-62-6P 500292-64-8P
500292-68-2P 500292-70-6P 500292-72-8P
500292-74-0P 500292-80-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrimidines as HIV inhibitors)

RN 500287-72-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (CA INDEX NAME)


Double bond geometry as shown.



RN 500287-94-5 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500287-96-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyano-1-propenyl]-2,6-
dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500287-98-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500288-00-6 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500288-02-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyano-1-methylethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


10/523,753RCE

Double bond geometry as shown.




RN 500288-04-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[2-cyano-1-(2-furanyl)ethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500288-06-2 CAPLUS


CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-4-fluoro- (9CI) (CA INDEX NAME)



RN 500288-08-4 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyano-4,4-dimethyl-3-oxo-1-pentenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 500288-40-4 CAPLUS

CN Butanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3-(2-furanyl)-5-methylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500288-43-7 CAPLUS


CN Propanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



10/523,753RCE


RN 500288-60-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-(1-chloro-2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500289-17-8 CAPLUS

CN 2-Thiopheneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-19-0 CAPLUS


CN 1,3-Benzodioxole-5-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-21-4 CAPLUS


CN 2-Naphthaleneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 500289-23-6 CAPLUS

CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-4-methoxy- (9CI) (CA INDEX NAME)



RN 500289-25-8 CAPLUS


CN Benzeneacetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-27-0 CAPLUS


CN 1H-Pyrrole-2-acetonitrile, α -[[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-1-methyl- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 500289-29-2 CAPLUS

CN 3-Thiopheneacetonitrile, α -[[4-[[2-[[4-(3,5-dimethylphenyl)methylene]amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-30-5 CAPLUS


CN Benzeneacetonitrile, 4-bromo- α -[[4-[[2-[[4-(3,5-dimethylphenyl)methylene]amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]- (9CI) (CA INDEX NAME)



RN 500289-31-6 CAPLUS

CN Benzeneacetonitrile, α -[[4-[[2-[[4-(3,5-dimethylphenyl)methylene]amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-3-methyl- (9CI) (CA INDEX NAME)


10/523,753RCE



RN 500290-59-5 CAPLUS

CN Butanedinitrile, [[4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylphenyl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500290-61-9 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-(cyanomethylene)propyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500290-63-1 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-1-(cyanomethylene)-2-methylpropyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500290-65-3 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-1-(cyanomethylene)-2-methylpropyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500290-85-7 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyano-1-methyl-1-propenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500292-32-0 CAPLUS


CN Benzonitrile, 4-[[4-[[4-(2-cyano-1-propenyl)-2-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/523,753RCE



RN 500292-40-0 CAPLUS


CN Benzonitrile, 4-[[4-[[2-chloro-4-(2-cyano-1-propenyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 500292-48-8 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500292-52-4 CAPLUS

10/523,753RCE

CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-(2-furanyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 500292-58-0 CAPLUS

CN Benzonitrile, 4-[[4-[[4-[(1Z)-2-cyanoethenyl]-2-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 500292-62-6 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-[(1E)-2-cyanoethenyl]phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/523,753RCE



RN 500292-64-8 CAPLUS


CN Benzonitrile, 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2-methoxyphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500292-68-2 CAPLUS


CN Benzonitrile, 4-[[4-[[2-bromo-4-(2-cyano-1-propenyl)-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500292-70-6 CAPLUS

CN Benzonitrile, 4-[[4-[[2-bromo-4-[(1E)-2-cyanoethenyl]-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



CN Benzonitrile, 4-[[4-[[4-(2-cyano-1-propenyl)-2-methoxyphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



CN Benzonitrile, 4-[[4-[[2-bromo-4-(2-cyano-1-propenyl)phenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 500292-80-8 CAPLUS

10/523,753RCE

CN Benzonitrile, 4-[[4-[[[2-chloro-4-[(1E)-2-cyanoethenyl]-6-methylphenyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:833290 CAPLUS

DN 135:371765

TI Preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors

IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne Alfons; Krief, Alain; Leenders, Ruben Gerardus George

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085700	A2	20011115	WO 2001-EP4991	20010503
	WO 2001085700	A3	20020207		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2406562	A1	20011115	CA 2001-2406562	20010503
	EP 1282606	A2	20030212	EP 2001-929616	20010503
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003535828	T	20031202	JP 2001-582301	20010503
	AU 783981	B2	20060112	AU 2001-56333	20010503
	US 2003171374	A1	20030911	US 2002-275931	20021108
PRAI	US 2000-202472P	P	20000508		
	WO 2001-EP4991	W	20010503		

OS MARPAT 135:371765

IT 373685-45-1P 373688-87-0P 373688-94-9P
373689-02-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors)

RN 373685-45-1 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-6-(trifluoromethyl)-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 373688-87-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(4-cyano-2,6-dimethylphenyl)amino]-2-[(4-cyanophenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 373688-94-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(4-cyano-2,6-dimethylphenyl)amino]-2-[(4-cyanophenyl)amino]- (9CI) (CA INDEX NAME)




RN 373689-02-2 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-(chloromethyl)-2-[(4-cyanophenyl)amino]-4-

10/523,753RCE

pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)




10/523,753RCE

L4 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:833289 CAPLUS
DN 135:371756
TI Preparation of prodrugs of HIV replication inhibiting pyrimidines
IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De
Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan;
Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne
Alfons; Krief, Alain
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085699	A2	20011115	WO 2001-EP4990	20010503
	WO 2001085699	A3	20020228		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2407754	A1	20011115	CA 2001-2407754	20010503
	AU 2001060277	A5	20011120	AU 2001-60277	20010503
	AU 782948	B2	20050915		
	EP 1282607	A2	20030212	EP 2001-933925	20010503
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003532713	T	20031105	JP 2001-582300	20010503
	US 2003186990	A1	20031002	US 2002-275333	20021107
	US 7034019	B2	20060425		
	US 2006009474	A1	20060112	US 2005-225839	20050913
PRAI	US 2000-202471P	P	20000508		
	WO 2001-EP4990	W	20010503		
	US 2002-275333	A3	20021107		
OS	MARPAT 135:371756				
IT	244767-86-0P 269055-06-3P 269055-07-4P 269055-40-5P 269055-46-1P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of prodrugs of HIV replication inhibiting pyrimidines)				
RN	244767-86-0 CAPLUS				
CN	Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)				

10/523,753RCE



RN 269055-06-3 CAPLUS

CN Benzonitrile, 4-[[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-07-4 CAPLUS


CN Benzonitrile, 4-[[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 269055-06-3

CMF C20 H16 Cl N7


10/523,753RCE



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 269055-40-5 CAPLUS


CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-46-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)

10/523,753RCE




10/523,753RCE

L4 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:628977 CAPLUS
DN 135:371702
TI Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues
AU Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J.
CS Janssen Research Foundation, Spring House, PA, 19477, USA
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(17), 2235-2239
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 135:371702
IT 244767-86-0P 244768-01-2P 269055-00-7P
269055-11-0P 269055-46-1P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and activity of diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors)
RN 244767-86-0 CAPLUS
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 244768-01-2 CAPLUS
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)

10/523,753RCE




RN 269055-00-7 CAPLUS

CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-11-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(4-cyano-2,6-dimethylphenyl)amino]-2-[(4-cyanophenyl)amino]- (9CI) (CA INDEX NAME)




RN 269055-46-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-

10/523,753RCE

3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:247156 CAPLUS

DN 134:280865

TI Preparation of azinylaminobenzonitriles and related compounds as virucides.

IN Verreck, Geert; Baert, Lieven

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001022938	A1	20010405	WO 2000-EP8522	20000831
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2384188	A1	20010405	CA 2000-2384188	20000831
	BR 2000014271	A	20020521	BR 2000-14271	20000831
	EP 1225874	A1	20020731	EP 2000-964080	20000831
	EP 1225874	B1	20060201		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	HU 200203568	A2	20030228	HU 2002-3568	20000831
	JP 2003510264	T	20030318	JP 2001-526150	20000831
	EE 200200151	A	20030415	EE 2002-151	20000831
	NZ 517025	A	20030725	NZ 2000-517025	20000831
	TR 200200763	T2	20030922	TR 2002-763	20000831
	AU 775360	B2	20040729	AU 2000-75127	20000831
	AT 316781	T	20060215	AT 2000-964080	20000831
	PT 1225874	T	20060630	PT 2000-964080	20000831
	ES 2258018	T3	20060816	ES 2000-964080	20000831
	SK 285240	B6	20060907	SK 2002-376	20000831
	IN 2002MN00145	A	20050318	IN 2002-MN145	20020131
	BG 106521	A	20021229	BG 2002-106521	20020314
	ZA 2002002289	A	20030620	ZA 2002-2289	20020320
	NO 2002001443	A	20020322	NO 2002-1443	20020322
	HK 1048768	A1	20060804	HK 2003-100992	20030211
	AU 2004224973	A1	20041125	AU 2004-224973	20041029
	US 2006127487	A1	20060615	US 2006-347071	20060203
PRAI	EP 1999-203128	A	19990924		
	WO 2000-EP8522	W	20000831		
	US 2002-88805	A3	20020321		

OS MARPAT 134:280865

IT 244767-86-0P 244768-01-2P 269055-00-7P

269055-06-3P 269055-07-4P 269055-11-0P

269055-40-5P 269055-46-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azinylaminobenzonitriles and related compds. as virucides)

RN 244767-86-0 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)

10/523,753RCE




RN 244768-01-2 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-00-7 CAPLUS


CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-06-3 CAPLUS

10/523,753RCE

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-07-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 269055-06-3


CMF C20 H16 Cl N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/523,753RCE


RN 269055-11-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(4-cyano-2,6-dimethylphenyl)amino]-2-[(4-cyanophenyl)amino]- (9CI) (CA INDEX NAME)



RN 269055-40-5 CAPLUS


CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-46-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)

10/523,753RCE



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:225202 CAPLUS

DN 134:256875

TI Controlled-release microparticle formulation for antiviral drugs

IN Hantke, Thomas; Rehbock, Bettina; Rosenberg, Joerg; Breitenbach, Joerg

PA Knoll A.-G. Chemische Fabriken, Germany

SO Ger. Offen., 16 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19945982	A1	20010329	DE 1999-19945982	19990924
	CA 2387536	A1	20010405	CA 2000-2387536	20000919
	WO 2001023362	A2	20010405	WO 2000-EP9149	20000919
	WO 2001023362	A3	20011206		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1214300	A2	20020619	EP 2000-964201	20000919
	EP 1214300	B1	20030903		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003518012	T	20030603	JP 2001-526516	20000919
	AT 248822	T	20030915	AT 2000-964201	20000919
	ES 2206304	T3	20040516	ES 2000-964201	20000919
	NO 2002001409	A	20020321	NO 2002-1409	20020321
PRAI	DE 1999-19945982	A	19990924		
	WO 2000-EP9149	W	20000919		
IT	244767-86-0 269055-06-3 269055-46-1				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (controlled-release microparticle formulation for antiviral drugs)				
RN	244767-86-0 CAPLUS				
CN	Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)				



10/523,753RCE


RN 269055-06-3 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-46-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:335393 CAPLUS

DN 132:347578

TI Preparation of arylaminopyrimidines as inhibitors of HIV replication.

IN De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Paul Adriaan Jan; Kavash, Robert W.; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons

PA Janssen Pharmaceutica N.V., Belg.; et al.

SO PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027825	A1	20000518	WO 1999-EP7417	19990924
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2350801	A1	20000518	CA 1999-2350801	19990924
	AU 9962008	A	20000529	AU 1999-62008	19990924
	AU 762523	B2	20030626		
	BR 9915552	A	20010814	BR 1999-15552	19990924
	TR 200101306	T2	20011022	TR 2001-200101306	19990924
	HU 200104177	A2	20020328	HU 2001-4177	19990924
	JP 2002529456	T	20020910	JP 2000-581005	19990924
	EE 200100252	A	20021015	EE 2001-252	19990924
	NZ 511116	A	20030829	NZ 1999-511116	19990924
	AP 1683	A	20061231	AP 2001-2121	19990924
	EP 1002795	A1	20000524	EP 1999-203590	19991101
	EP 1002795	B1	20030305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1270560	A1	20030102	EP 2002-18455	19991101
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	AT 233740	T	20030315	AT 1999-203590	19991101
	US 2003114472	A1	20030619	US 1999-430966	19991101
	US 6878717	B2	20050412		
	PT 1002795	T	20030731	PT 1999-203590	19991101
	ES 2193664	T3	20031101	ES 1999-203590	19991101
	TW 238161	B	20050821	TW 1999-88119614	19991223
	HK 1025330	A1	20030613	HK 2000-104633	20000726
	HR 2001000161	A1	20020228	HR 2001-161	20010307
	NO 2001001696	A	20010404	NO 2001-1696	20010404
	NO 318801	B1	20050509		
	BG 105418	A	20011130	BG 2001-105418	20010406
	IN 2001MN00436	A	20050304	IN 2001-MN436	20010420
	ZA 2001003769	A	20020812	ZA 2001-3769	20010509
	US 2004039005	A1	20040226	US 2003-634682	20030805
	US 7037917	B2	20060502		
	US 2005288278	A1	20051229	US 2005-204513	20050816
PRAI	US 1998-107792P	P	19981110		
	US 1999-143962P	P	19990715		
	US 1998-107792	P	19981110		

10/523,753RCE


US 1999-143962 P 19990715
WO 1999-EP7417 W 19990924
EP 1999-203590 A3 19991101
US 1999-430966 A1 19991101
US 2003-634682 A1 20030805
OS MARPAT 132:347578
IT 269055-00-7P 269055-07-4P 269055-12-1P
269055-40-5P 269055-46-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylaminopyrimidines as inhibitors of HIV replication)
RN 269055-00-7 CAPLUS
CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-07-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 269055-06-3
CMF C20 H16 Cl N7




10/523,753RCE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 269055-12-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(4-cyano-2,6-dimethylphenyl)amino]-2-[(4-cyanophenyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 269055-11-0


CMF C21 H15 N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 269055-40-5 CAPLUS


CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)

10/523,753RCE



RN 269055-46-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:640840 CAPLUS

DN 131:257576

TI Preparation of HIV inhibiting pyrimidine derivatives

IN Andries, Koenraad Jozef Lodewijk Marcel; De Corte, Bart; De Jonge, Marc
 Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Marcel August Constant;
 Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; Kukla, Michael
 Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons

PA Janssen Pharmaceutica N.V., Belg.; et al.

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9950250	A1	19991007	WO 1999-EP2043	19990324
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 945442	A1	19990929	EP 1998-201587	19980514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2324919	A1	19991007	CA 1999-2324919	19990324
	CA 2324919	C	20061017		
	AU 9935996	A	19991018	AU 1999-35996	19990324
	AU 751573	B2	20020822		
	BR 9909191	A	20001205	BR 1999-9191	19990324
	HU 200101204	A2	20011028	HU 2001-1204	19990324
	EE 200000532	A	20020215	EE 2000-532	19990324
	JP 2002509920	T	20020402	JP 2000-541155	19990324
	JP 3507917	B2	20040315		
	AP 1468	A	20050930	AP 2000-1912	19990324
	W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW				
	BG 104738	A	20010430	BG 2000-104738	20000830
	BG 64702	B1	20051230		
	HR 2000000620	A1	20010630	HR 2000-620	20000919
	IN 2000MN00426	A	20050304	IN 2000-MN426	20000922
	NO 2000004810	A	20000926	NO 2000-4810	20000926
	NO 317424	B1	20041025		
	HK 1035901	A1	20060324	HK 2001-106524	20010914
PRAI	US 1998-79632P	P	19980327		
	EP 1998-201587	A	19980514		
	EP 1998-203948	A	19981125		
	WO 1999-EP2043	W	19990324		

OS MARPAT 131:257576

IT 244767-86-0P 244767-94-0P 244768-01-2P


244768-02-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of HIV inhibiting pyrimidine derivs.)

RN 244767-86-0 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)

10/523,753RCE




RN 244767-94-0 CAPLUS

CN Benzonitrile, 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 244768-01-2 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 244768-02-3 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-


10/523,753RCE

3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 244768-01-2


CMF C21 H18 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/523,753RCE

L4 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:631415 CAPLUS

DN 131:257575

TI Preparation of arylaminopyrimidines for treatment of human immunodeficiency virus infection.

IN Andries, Koenraad Jozef Lodewijk Marcel; De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Marcel August Constant; Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons

PA Janssen Pharmaceutica N.V., Belg.

SO Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 945443	A1	19990929	EP 1999-200918	19990324
	EP 945443	B1	20030212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 945442	A1	19990929	EP 1998-201587	19980514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EP 1245567	A1	20021002	EP 2002-14566	19990324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1998-79632P	P	19980327		
	EP 1998-201587	A	19980514		
	EP 1998-203948	A	19981125		
	EP 1999-200918	A3	19990324		


OS MARPAT 131:257575

IT 244767-86-0P 244767-94-0P 244768-01-2P
244768-02-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylaminopyrimidines for treatment of HIV infection)

RN 244767-86-0 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl- (CA INDEX NAME)




RN 244767-94-0 CAPLUS

CN Benzonitrile, 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-


10/523,753RCE

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 244768-01-2 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 244768-02-3 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 244768-01-2

CMF C21 H18 N6


10/523,753RCE



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:482150 CAPLUS

DN 115:82150

TI Spectrally sensitized silver halide photographic material containing bisaminopyrimidine derivative

IN Takei, Haruo; Ikeda, Tadashi

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 19 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03015042	A	19910123	JP 1989-150264	19890613
PRAI	JP 1989-150264		19890613		
IT	134917-70-7				


RL: TEM (Technical or engineered material use); USES (Uses)
(photog. emulsion containing)

RN 134917-70-7 CAPLUS

CN Benzenesulfonic acid, 2,2'-(1,2-ethenediyl)bis[5-[[2,6-bis[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-, disodium salt (9CI) (CA INDEX NAME)

PAGE 1-A





10/523,753RCE .

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

152.98

325.74

STN INTERNATIONAL LOGOFF AT 16:27:23 ON 22 MAY 2007